PMEF
OVID icon

Point72 Middle East FZE’s Ovid Therapeutics OVID Stock Holding History

Point72 Middle East FZE’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,993
Closed -$15.5K – 1935
2023
Q1 		$15.5K Buy
+5,993
New +$14.2K ﹤0.01% 1454

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Middle East FZE's OVID Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Ovid Therapeutics (OVID) in Q2 2023, closing a stake of 5,993 shares — an estimated $15.5K sold.

Point72 Middle East FZE first reported a position in OVID in Q1 2023 and held it in 1 quarter. The position peaked at $15.5K in Q1 2023. 69 funds tracked by Wall St. Rank hold OVID as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Ovid Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 5,993 Ovid Therapeutics shares in Q2 2023, an estimated $15.5K.
  • Point72 Middle East FZE first reported a position in Ovid Therapeutics in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Ovid Therapeutics position peaked at $15.5K in Q1 2023.
  • 69 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.